newsfilter
← Latest News
Earnings Call Transcripts·

ARCUS BIOSCIENCES, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - ARCUS BIOSCIENCES INC

Hey, good afternoon. Hey, good afternoon, everyone. Thank you to those of you in the room, as well as those of those of you dialed in. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Arcus Biosciences. We've got Terry and Bob on stage with me. A lot to talk through. You guys got a ton of data recently, a lot more coming up. Terry, can I pass it to you to introduce the company? Sure, so I'll try to do this quickly, because I know we want to focus on these new data but since there may be some people new to Arcus, I'm just gonna give you a brief overview of the company, kind of bringing you from the founding of the company up until today. So, Arcus was founded in roughly 10 years ago. Our focus has been really on small molecule drug discovery. We tend to play where there's strong biological validation, but for one reason or another, there's not a great molecule, So CasDataFan really fits right down the middle there. If you look at, fast forward to where we are now, we have a portfolio of programs, a lot of them in the immunology area. They fit that general paradigm of a great molecule, highly validated target. We have a readout coming, an interim analysis of our Phase III program for a drug called Quemliclustat in frontline pancreatic cancer that's going to read out later this quarter. So the quarter's almost over, so we'll be there shortly. And then really the focus of the company is CasDataFan. That's where our resources are, whether they're people, dollars, or studies. And so we look at casdatofan as a huge opportunity. It's a two-horse race, and in some cases it's only one-horse race. So basically there's one other molecule. It's belzodifan. The reason that there's only two molecules, it comes a little back to what I was saying about the focus of the company. So HIF-2, which is the target for this molecule, is a very difficult target. And in fact, to give you a bit of perspective in history, the original work that informed what became Belzudafan was done at University of Texas Southwestern. They solved a structure for what was in the past thought to be an undruggable target, HIF-2-alpha. Then Peloton was formed. They came up with this drug, Belzutafan, and Merck acquired Belzoutafan. Belzodifan has a primary limitation, and that's that it has absorption-limited pharmacokinetics. So it was very hard to sort of get all the other right things from a drug perspective and get that piece fixed, and Casdatofan really addressed that. And so we showed in a number of ways, including a lot of this is in a recent Nature publication, how much better Casdatafan is at inhibiting HIF-2-alpha. And it's most notably, you can see that when you look at the biomarker data for HIF-2-alpha inhibition in a human. So if you compare what casdatofan does versus what belzutafan does, basically casdatafan can hammer this target out past a year, and belzotafan essentially loses the majority of effect sometime between one and 13 weeks. And so we've shown in a number of studies that casdatofan looks now better clinically, and it can be tied back to that biomarker data and those PK advantages. So to just summarize the recent data that we'll be getting into much more deeply today, we've showed data in the front line where basically we're going against a standard of care that will be ipinevo. we've shown data in the second line where standard of care is cabozantinib and we've shown data in the late line where basically we're looking at monotherapy data right now and we'll be doing a combination study and across those lines of therapy whether you're looking at rate of primary progression whether you are looking at response rate whether you looking at PFS and now most recently overall survival so overall survival is an endpoint on which Merck has not hit in any of three trials. And the data we've just shown gives us good reason to believe, and I think the clinical community, that we'll be able to show an overall survival advantage in every line of therapy and, in fact, address what are the limitations of the standard of care in each line of therapy. So we think this is a $5 billion to $10 billion drug that will be able to be used in consecutive therapies. There's been no evidence of resistance development. So a patient, not only will you have these advantages, but you'll have a very long duration of therapy. So we're well capitalized. The cash that we have takes us into 2029. That's on the other side of our initial registrational trials. Reading out, our first registritional trial with Casdatafan is called Peak 1. We expect it to be enrolled, fully enrolled within the next month or two. And then our second registration of trial, which is about to start by the end of this year, that's really our brass ring because that's the front line. We've shown advantages in our early data. That's about to star. And so I'll stop there and take questions. Yeah, let's start on, so peak one, you're running that study. remind us the designs for that second line RCC comparing to Cabo monotherapy right so the the comp here for Belzudafen is light spark 11 that we recently saw some more data for it's a pretty nuanced kind of concept of comparing your arc 20 your early stage kind of second line RCC data set to light spark eleven can you walk us through the nuances of how to compare those two data sets because you know at a top line level they both land in about 14 and a half months but it's it's different for reasons I think you guys explained well so I want you to I want to give you the opportunity to yeah sure I think when you think about doing the cross trial comparison you have to think about probably a couple of things most notably is the patient population and a large portion of the difference between the patient populations is due to when the studies were enrolled in the global footprint from those studies. So in the registrational study, Light Spark 11, that Merck conducted, the study structure, first of all, was somewhat unusual. It was lenvatinib plus Belzudafan versus cabozantinib, which is the widely accepted standard of care in the second line. As a result, that study precluded prior treatment with both of those TKIs, lenvatnib as well as cabozantinib, which is a large portion of what frontline patients receive today. And the other piece of their study probably that was more due to the timing of it and the global footprint of the study was that they enrolled a very large percentage of the patients that had received older generation TKIs. So these are drugs like sunitinib and pazopinib that are no longer standard of care in the U.S. or in most major markets. And so a study that would be enrolled today, like our Phase II ARC-20 study, would not see significant representation from those patients. So why is that important? Like, those patients generally tend to perform well on subsequent TKI current generation therapy. And so in the LightSpark 11 study, now we've seen some subpatient population analyses that Merck shared at ESMO, which showed that those patients outperformed the remainder of the patients in the study. And, in fact, they were about a third of the patient population. We don't expect to see those patients in our study, and therefore, you know, we would expect a different performance. Got it. So she kind of put it at a high level. Essentially, they selected for patients who hadn't been treated with the optimal TKI, so they saw better efficacy when they're looking at their TKI combo. Is that a fair way to simplify it? I think the way to simply say it is the patient population that we're running in looks very much like the real-world patient population. And 60% of the patients that come into that are going to have received a second-generation TKI. Those patients perform more poorly on what's the control arm for both our study and the Merck study. And, in fact, the subpopulation data that Bob discussed showed exactly that. So the totality of our data suggests that we're going to have two advantages relative to what Belzudafan and Lemba showed. First of all, we're gonna give those patients that get a second generation that would otherwise do poorly, they do as well or better on Cas-Cabo. The second piece is that, for the first time, we showed data not only in our late line, but in this study in ARC-20, that suggests a very strong probability, and in fact, I'd say virtual certainty, that we're going to show an overall survival advantage. That's viewed as something that would essentially cannibalize the entire second-line market. So we'll have both that OS advantage that Merck didn't show and then we'll have the advantage in that 60% of the patients that would otherwise be underserved by a subsequent TKI therapy that Cascavo will serve well. Yeah, it makes sense. And I understand the differences that you're pointing out between ARC20 and LightSpark11 with respect to prior TKI exposure. How would you recommend thinking about the comparability of those patient populations with respect to other factors like high risk versus lower risk, prior lines of therapy, things like that? Otherwise, things are pretty much the same. And that's probably the most important single effect in the study. A lot of times people look at all sorts of demographics. Those other demographics become rounding errors versus the prior TKI treatment. Got it. Okay, that makes sense. And then as you guys think about, you know, the CABO benchmarks for sort of a more representative patient population, can you talk about, I mean, what sources you're looking at, what you would point investors towards in terms of thinking about what CABO looks like, you know, more contemporary pre-treated population? Sure. I think you could look at the LightSpark 011 CABO population. You can look at past approvals for Cabo itself, or you could look at Cabo control arm. And generally what you've seen is a pretty consistent number that's about, if you looked at a median PFS, of about 10 months. Our Cabo arm will probably be somewhere more in the 9-ish months, just because basically none of those CABO cohorts had the second-generation TKIs in any meaningful respect. LightSpark 011 had maybe 25% of exitinib. There's been no study where there's been a meaningful contribution of limbatinib patients. Those limbatinab patients performed the poorest. We showed in our ARC-20 study that those Lembatten patients do great on Cas-Datafan-Cabo, and you should expect high teens to 20-ish percentage of Lemba patients in our study. So what those are going to do is drive the performance of the Cabo arm down, while at the same time actually elevating the performance of the Cas-Cabo arm. So from a hazard ratio standpoint, it's very positive. And it's a nice thing because that hazard ratio is really representing a very important benefit to patients because those cobble-treated patients where they'd been pretreated with Lemba would otherwise do quite poorly. And you're bringing them back as if they hadn't been treated with that Lembatinib. Got it. And then you mentioned you're going to complete enrollment in peak one within the next couple of months here. Can you just lay out, at least at a high level, what we should be expecting in terms of timeline to read out? And another thing, you pointed out the relative importance of being able to show OS. Is that something that we should expect at the outset when we first get data, or is that something we'll need to mature over time? So the timing, while we haven't given specific guidance, If you just do the math based upon this is a PFS readout, it should take about a year to read out, so sometime in the earlier part of 2028. PFS is critical. That's the primary endpoint. But a nice thing is the way our stats plan is designed is with PFS as the primary end point, all of our alpha is on the PFS. But since it's a hierarchical analysis, if we hit on PFS, all of the alpha goes on to OS. So it's very possible we could see an OS hit at that initial readout, but the study is designed to have subsequent readouts. But PFS will get us there for an approval, and we'll see if we show the OS at the first analysis or not. Got it. That makes sense. And then can you talk about safety profile and ability to safely deliver this combination and what that looks like in terms of dose intensity that you observed so far, both for your drug and for the CABO combo partner? So, go ahead. Yeah, I think the most important part is if you think about, like, certainly comparing to, like the LightSpark 11 regimen, which delivered a positive pivotal study, in general physicians find it easier to manage the toxicity of cabozantinib. And we've seen a very similar safety profile from casdatafan and belzutafan. So our expectation is that the combination should be quite manageable, and that's been the clinical experience that we've seeing so far. And so don't expect any challenges from a dose intensity perspective. Got it. In fact, like in our late-line monotherapy with our drug, Even though the most pronounced on-target adverse event is anemia, we had zero discontinuations in over 100 patients from that AE. Got it. So I think that makes a ton of sense on second-line RCC. I want to shift gears and talk about the first-line setting. Terry, you mentioned you had a little initial teaser of some nice front-line data last month. Before we get into that, can you just talk about, from a strategy development perspective, How did Belzudifan approach the frontline setting, and how are you approaching the frontline setting? So Belzutifan has an issue that didn't enable them to approach the way we did. So basically, when we first got into this program, what investigators told us was the ideal therapy would be a TKI sparing regimen that built upon ipinivo. And ipinevo is the most used regimen in the front line. It's used 30%. Why isn't it used? 90%. And iponevo gives great survival, so it gives the best survival of any regimen, but it has a relatively high rate of primary progression, almost one in five patients. That's sort of a devastating effect for both the patients and the investigators. So the key thing would be to drive down that rate of primary progression, get the disease control. Also, just even PFS. Ipi Nivo has a 12-month landmark survival, landmark PFS of about 50%. So Merck, because Belzudifan has a relatively high rate of primarily progression itself, is somewhat forced to combine with the TKI. So the very strategy that we're pursuing of going for TKI sparing regimen, not only for a number of reasons, that's just the baggage from a patient tolerability standpoint of not having to take the TKI, but also that TKI induces more HIF-2-alpha activity, which is why those patients tend to perform more poorly going forward. So strategically, our focus was very simple. IPI and NEVO combined with CasDataFan, reduce the rate of primary progression, drive all of the other variables, whether it's OR, RPFS, and keep that OS that's associated with it. That would be a huge win, and we think we're on track to do that. And, in fact, our early data are clearly showing that that's exactly what CasDataFan brings. CasDatafan brings the same disease control that you see with a TKI without the baggage of the TKI. Got it. And then, Terry, just to kind of like ask you to defend this a little bit more, right, like as someone new coming into the story, right? Like at a surface level, you would look at this and say, all right, there is a regimen that is used in about a third of frontline renal cell cancer. Why are you combining with that instead of TKI that's used in the majority of a front line? Right. So the reason is because that high rate of primary progression, the TKIs address that. And so when you basically get to a rate of primarily progression with all of those that's less than 10%, but the best survival comes from the if being evil. so it's essentially like saying oh you use chemo for this and you have this good thing but the good thing, why are you combining with the good thing, not the chemo and because the idea is that you're going to drive and in fact this is, let me show you the data or tell you about the data that we've already generated basically what we're looking to do is bring the PFS and the primary progression towards what you see with those TKIs, and essentially you're going to take that entire large part, you're gonna drive that 30% to certainly greater than 50%. And what we've already shown is that when you combine CasDataFan with either just anti-PD-1 alone or anti-PD-1 and IPI, basically you're seeing a rate of primary progression that's like in the five-ish or 6%. So you've already achieved that part. Then what we've also shown is just even without the IPI, because we ran this first with just anti-PD-1, if you looked at, as I mentioned, the landmark PFS for IPI-NEVO is about 50% at 12 months. We're at like 69%. is like 70%, Axi or Cabo and Anti-PD-1 is less than that. So we're basically generating the same sort of data that you see with the TKI, Anti- PD-1, but without the baggage. Got it. And then just remind us, with respect to Phase 3 progress on frontline, ipinevo, combo, where are we at on that? Full speed, that'll be starting by the end of this year. We'll probably have first patient in early next year. So the key thing that was rate limiting on that was generating safety data. When you talk about ipi-nevo, what that really means is you get four cycles of ipi nevo, then you get nevo. So essentially you're going to get four circles, 12 weeks of ipinevo-cas, then you're gonna get nevocas. And for both the FDA and EMA, we generated the data in roughly 25 patients that they want to see from a safety standpoint to start the study. We've generated those, and we're full speed ahead to start to study. Well, can you talk about that strategy and how it differs from LightSpark 12? Sure. So LightSpARK 12, the biggest difference is the molecule itself. Belzodifan, the durability of its robust inhibition of HIF-2 is very short. And you're comparing to a control arm that has 24 months, essentially, PFS. So any effect it's having is getting diluted out. And then Lemvopembro is a pretty toxic regimen, and Lemvapembro-Bells is even more toxic. So you basically, what you saw in LightSpark-012 was about a greater than 50% rate of discontinuation. So you had all sorts of issues on that, and you're not bringing much efficacy to the table. So not surprisingly, they had a hazard ratio that was in the one range. We would be combining with Exitinib, which is a milder, gentler TKI. It's a more specific TKI in terms of its target activity. Lemva hits FGF receptor. It makes it very anti-angiogenic, but that's what brings a lot of its toxicity as well. What I'll also mention, so in addition to the key thing being that casdatofan is going to bring durable efficacy without that safety signal where you didn't see that with belazodafan, The other thing that we're exploring is we have three collaborations, for those of you who are new to ARCIS, with the BMS, Summit, and Pfizer with their anti-PD-1 VEGF bispecifics. So we actually think that those have an opportunity to be a better version of TKI anti-PD-1 because you're getting the VEGF activity without the baggage of the TKI, and all three of those studies are initiating now. And it wouldn't surprise us if we were starting a Phase III study with one or more of those by the latter part of next year. Got it. So, Terry, just to kind of wrap up here, you know, I'm kind of new to your story as well, And I would say, welcome. Yeah. You know, in some ways, it's like super simple, right? Is that you have a better HIF-12 inhibitor and you're going to blanket the RCC landscape. But it's also very complicated at the same time. There's several moving parts. As you're talking to new investors, what do you think is the kind of or even, you know, existing investors as well? Like, what Do you think Is the biggest thing that people kind of struggle with or misunderstand about Arcus? I think it's the part that you said about the complexity. The complexity is actually really simple. So I think we're going to have a lot of data that we share. It's going to be a milestone-rich year in 2027. And a lotof the data thatwe're goingto show, I thinkwe've gotten to an inflection, but this year is really goingto, you know, put the stamp on that. So peak one's goingto be fully enrolled. We're going to be heading towards that readout in the first part of 2028. You're going see more data for the front line that amplifies what we've already seen, that people now will see two cohorts, a doublet and a triplet, that just blow away what you see in the front lines. They'll get how simple that is. In each case, we're going on top of the standard of care and simply addressing what's the limitation of that standard ofcare. And the second line will now show, we showed early OS data in the second line, but with another six months or so of maturity, it's going to be obvious that what we showed in the late line, which was three years of overall survival where Belzudafan has essentially 20 months. So you're going to start to see the same advantage in the second line where what we're going against is a cabozantinib that has a 20-month OS, that that OS signal will become very obvious to people. And I think the simplicity will be obvious in the idea that since you don't develop resistance to Casdatafan or HIF-2-alpha inhibition in general, that this can be a therapy that patients are on for 5, 10 plus years. So the durability of treatment, not only great for patients, but the commercial opportunity. This This is truly a $10 billion drug, and the front line, where essentially the biggest opportunity, brass ring, there's no competition. Simply beat epinephrine. I think that'll become very clear as we go through the year and share more data. Got it. Awesome. Well, I think this is all we have time for. Thank you so much, Terry and Bob, for being with us here. Thanks for inviting us to the conference. It was great. I appreciate it.

Company
ARCUS BIOSCIENCES INC
Keywords
ARCUS BIOSCIENCES INC